electroCore Expands Intellectual Property Portfolio
02 April 2024 - 2:00PM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced that it has received
patent issue notifications from the United States Patent and
Trademark Office (USPTO). The two patents were issued on April 2,
2024, and relate to electroCore’s non-invasive vagus nerve
stimulation (nVNS) technology:
- US Patent No. 11,944,815 entitled
“Non-Invasive Nerve Stimulation with Mobile Device” generally
relates to a system for transcutaneously stimulating a nerve in a
patient that includes a downloadable software application
configured to wirelessly transmit a therapy regimen to a
stimulator. The therapy regimen comprises generating an electrical
signal for approximately 5 minutes to 30 minutes.
- US Patent No. 11,944,807 entitled
“Vagal Nerve Stimulation for Treating Central Nervous System
Disorders” generally relates to methods for treating central
nervous disorders, such as PTSD, fibromyalgia, anxiety and TBI by
applying electrical impulses to the vagus nerve according to a
stimulation protocol that includes at least two doses each day. The
electrical impulses are bursts of 2 to 20 sinusoidal pulses.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents providing expanded IP coverage; the
possibility of future business models, the potential of nVNS
generally and gammaCore in particular and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to obtain
additional financing necessary to continue electroCore's business,
sales and marketing and product development plans, the
uncertainties inherent in the development of new products or
technologies, the ability to successfully commercialize gammaCore™,
competition in the industry in which electroCore operates and
general market conditions. All forward-looking statements are made
as of the date of this press release, and electroCore undertakes no
obligation to update forward-looking statements or to update the
reasons why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024